

The Genetics Company, Inc.

CONTACT DETAILS

The Genetics Company, Inc.
 Wagistrasse 23, 8952 Schlieren, Zurich, Switzerland
www.the-genetics.com; info@the-genetics.com
 Tel: +41 44 200 22 00, Fax: +41 44 200 22 11

COMPANY PROFILE

The Genetics Company is a dedicated team of entrepreneurs and scientists focusing on the research, development and commercialization of innovative products for the diagnosis, therapy and treatment monitoring of patients suffering from neurodegenerative disease or from cancer.

In 2002, the Company acquired key assets from CallistoGen AG, Berlin, Germany in order to substantially strengthen its in-house chemistry capabilities and to expand its product pipeline. This transaction was complemented by the acquisition of German Alzheimer's disease specialist, Abeta GmbH, core business in 2003, which fortified the Company's Alzheimer's program and established a platform for the development and marketing of world leading products for the diagnosis of Alzheimer's disease.

These diagnostics products have already attracted a wide range of customers including major international pharmaceutical and biotech companies as well as renowned academic laboratories.

Located at the Biotech Center Zurich (Schlieren), Switzerland, the Company currently employs a total staff of 8.

FINANCIAL SUMMARY

The Company became operational following the closure of its Series A financing round in May 2000, which raised a total of CHF 10.5 Mio in equity. In November 2003 the Company completed a CHF 14 Mio Series B financing round, co-led by existing shareholders Nextech Venture and Novartis Venture Fund. New investors included Najeti Capital, a leading Spanish venture capital firm from Madrid, Heidelberg Innovation of Heidelberg, Germany and several high net worth individuals.

In February 2005 a Series C financing round was closed with a volume of CHF 25 Mio. While a total of CHF 17 Mio has been committed upfront, an additional installment of CHF 8 Mio is associated with the achievement of certain clinical milestones in 2007. This round was co-led by Nextech Venture, Novartis Venture Fund and a major new investor, Varuma AG of Basel.

EXECUTIVE MANAGEMENT

Dr. Mátyás Végh
 Chief Executive Officer
vegh@the-genetics.com

PRODUCT OPPORTUNITIES & TECHNOLOGIES

- A unique set of diagnostic kits and tools for the diagnosis and monitoring of patients suffering from Alzheimer's disease (AD) and for use in pre-clinical Alzheimer's disease research.
- Small molecule inhibitors of Bcl-9, an essential protein for Wnt-signaling, a physiological process found to be aberrantly overactive in more than 85% of colorectal and 65% of liver cancers. Lead compounds could enter IND-enabling studies in year 2008 and clinical trials are expected to start in 2009.
- Small molecule inhibitors of hPygopus, a second proprietary drug target in Wnt-signaling / cancer, have been generated. These compounds are being profiled for potential therapeutic use.

BOARD OF DIRECTORS

Mr. Hans-Beat Gürtler	Partner, Varuma AG, Switzerland
Dr. Rudolf Gygax	Vice Chairman; Managing Director, Novartis Venture Fund, Switzerland
Dr. Peter Rickli	Partner, Christen Rickli Partners, Switzerland
Dr. Alfred Scheidegger	Chairman; Founder of Nextech Venture AG, Switzerland

KEY SCIENTIFIC ADVISORS

Prof. Michel Aguet	Director, Swiss Institute for Experimental Cancer Research (ISREC), Switzerland; Co-Founder
Prof. Adriano Aguzzi	Institute of Neuropathology, University Hospital, Switzerland
Prof. Konrad Basler	Institute of Molecular Biology, Zurich University, Switzerland; Co-founder
Prof. Konrad Beyreuther	Center for Molecular Biology Heidelberg (ZMBH), Heidelberg University, Germany
Prof. Ernst Hafen	Institute for Molecular Systems Biology (IMSB) ETH Zurich, Switzerland; Co-founder
Prof. David Livingston	Dana-Farber Cancer Institute, Harvard Medical School, USA
Prof. Leonardo Scapozza	Inst. of Pharmaceutical Biochemistry, University of Geneva, Switzerland